制药医学发展概况及学科建设展望

doi:10.3969/j.issn.1006-7795.2023.01.001

首都医科大学学报

• 专家述评 •

制药医学发展概况及学科建设展望

王安心^1,2,3, 夏雪^1,2,3, 朱金巧^1,3, 陈倩楠^3,4, 胥芹^1,2,3, 张怡君^1,2,3, 张晓丽^1,2,3, 李静^1,2,3, 田雪⁵, 罗会⁵, 王拥军^1,2,3*

1.首都医科大学附属北京天坛医院神经病学中心,北京 100070;
2.首都医科大学附属北京天坛医院国家神经系统疾病临床医学研究中心,北京 100070;
3.首都医科大学临床流行病学与临床试验学系,北京 100070;
4.北京市神经外科研究所,北京 100070;
5.首都医科大学公共卫生学院,北京 100069

收稿日期:2022-10-24 发布日期:2023-01-13
基金资助:
国家重点研发计划(2022YFC3600600,2022YFC3600603),首都医科大学附属北京天坛医院院科研基金(管理专项)(TYGL202220)。

The development of pharmaceutical medicine and the prospect of its discipline construction

Wang Anxin^1,2,3, Xia Xue^1,2,3, Zhu Jinqiao^1,3, Chen Qiannan^3,4, Xu Qin^1,2,3, Zhang Yijun^1,2,3, Zhang Xiaoli^1,2,3, Li Jing^1,2,3, Tian Xue⁵, Luo Hui⁵, Wang Yongjun^1,2,3*

1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
2. China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
3. Department of Clinical Epidemiology and Clinical Trials, Capital Medical University, Beijing 100070, China;
4. Beijing Neurosurgical Institute, Beijing 100070, China;
5. School of Public Health, Capital Medical University, Beijing 100069, China

Received:2022-10-24 Published:2023-01-13
Contact: *E-mail:yongjunwang@ncrcnd.org.cn
Supported by:
National Key Research and Development Program (2022YFC3600600, 2022YFC3600603), the Research Fund of Beijing Tiantan Hospital, Capital Medical University (Management Special Fund) (TYGL202220).

摘要/Abstract

摘要： 制药医学是医学的一个分支学科,专注于创新药物的研发,涉及药物临床研究与评价、药政管理部门的监管和批准等多个环节。自20世纪中叶以来,系统的制药医学在以英国为代表的发达国家中不断发展,并逐步形成了一套完善的制药医学人才培养体系,为全球的公共卫生和健康事业作出了巨大的贡献。当前,我国正处于由仿制药生产向创新药研发转型的关键时期,亟需大批有专业知识和实践经验的制药医学专业人才。因此,积极探索开展制药医学学科建设,完善新药研发人才的早期系统教育,显得尤为必要。本文将概述制药医学的发展历史与国际国内现状,以此为基础,提出对我国制药医学建设的思考与建议,并对当前该领域内的探索性工作进行简要介绍。

关键词: 制药医学, 学科建设, 人才培养

Abstract: Pharmaceutical Medicine is a branch of medicine, focusing on the research and development of innovative drugs, involving clinical research and evaluation of drugs, supervision and approval by drug administration departments and so on. Since the middle of the 20th century, pharmaceutical medicine has been developing continuously in developed countries like the United Kingdom. It has gradually formed a set of systematic pharmaceutical medical personnel training system, making a great contribution to the global public health and wellness. At present, China is in a critical period of transformation from generic drug production to innovative drug research and development, and many pharmaceutical and medical professionals with both theoretical knowledge and practical experience are urgently needed. Therefore, it is particularly necessary to explore the construction of pharmaceutical disciplines and to improve the early systematic education of new drug research and development talents. In this paper, the development history and current situation of pharmaceutical medicine worldwide were reviewed. Furthermore, the thoughts and suggestions on the construction of pharmaceutical medicine in China were put forward, and the current exploratory work was briefly introduced.

Key words: pharmaceutical medicine, discipline construction, cultivation of talents

中图分类号:

王安心, 夏雪, 朱金巧, 陈倩楠, 胥芹, 张怡君, 张晓丽, 李静, 田雪, 罗会, 王拥军. 制药医学发展概况及学科建设展望[J]. 首都医科大学学报, doi: 10.3969/j.issn.1006-7795.2023.01.001.

Wang Anxin, Xia Xue, Zhu Jinqiao, Chen Qiannan, Xu Qin, Zhang Yijun, Zhang Xiaoli, Li Jing, Tian Xue, Luo Hui, Wang Yongjun. The development of pharmaceutical medicine and the prospect of its discipline construction[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2023.01.001.

参考文献

[1] Faculty of Pharmaceutical Medicine. What is pharmaceutical medicine?[EB/OL]. (2019-12-05)[2022-10-09]. https://www.fpm.org.uk/our-specialty/what-is-pharmaceutical-medicine/.
[2] 刘雅莉, 谢琪, 刘保延, 等. 临床试验百年历程概述[J]. 中国循证医学杂志, 2016, 16(11): 1241-1249.
[3] Anon. IFAPP directory[J]. Int J Pharm Med, 2000, 14(2): 111.
[4] IFAPP. The PharmaTrain Syllabus for pharmaceutical medicine/medicines development science (version 2.0) 2018[EB/OL]. (2018-01-01)[2022-10-09]. https://ifapp.org/about/pharmatrain-syllabus.
[5] Luscombe D K, Salek M S. An international postgraduate course in pharmaceutical medicine: a 25-year review[J]. Int J Pharm Med, 2001, 15(6): 261-263.
[6] Stonier P, Silva H, Lahon H. Pharmaceutical medicine: history, global status, evolution and development[J]. Int J Pharm Med, 2007, 21(4): 253-262.
[7] Goldberg A, Smith R N. Pharmaceutical medicine[J]. Lancet, 1985, 1(8426): 447-448.
[8] Gabbay F J, Stonier P D. Pharmaceutical medicine: a recognized medical discipline? Have we got the message across?[C]. Ruiz Ferr'an J. Communication in pharmaceutical medicine: a challenge for 1992. Seventh International Conference on Pharmaceutical Medicine, 1990 Sep 23-26; Madrid, Spain. Barcelona: Prous Science Publishers, 1991: 369-374.
[9] Morris T, Brostoff J M, Stonier P D, et al. Evolution of ethical principles in the practice of pharmaceutical medicine from a UK perspective[J]. Front Pharmacol, 2020, 10: 1525.
[10] ABPI. Innovative Medicines Fund (IMF)[EB/OL]. (2022-03-10)[2022-10-09]. https://www.abpi.org.uk/value-and-access/innovative-medicines-fund-imf/.
[11] Criscuolo D. Postgraduate courses in pharmaceutical medicine in Italy[J]. Front Med (Lausanne), 2017, 4: 79.
[12] Farmindustria. Indicatori farmaceutici: LUGLIO 2022[EB/OL]. (2022-07-01)[2022-10-09]. https://www.farmindustria.it/app/uploads/2022/07/IndicatoriFarmaceutici2022.pdf.
[13] Die Publikationsplattform des Bundesrechts. Verordnung über klinische Versuche mit Ausnahme klinischer Versuche mit Medizinprodukten (Verordnung über klinische Versuche; KlinV)[EB/OL]. (2013-06-01)[2022-10-09]. https://www.fedlex.admin.ch/eli/cc/2013/643/de.
[14] SIWF. Fortbildungsprogramm (FBP) der Schweizerischen Gesellschaft für Pharmazeutische Medizin (SGPM)[EB/OL]. (2011-07-19)[2022-10-09]. https://siwf.ch/files/pdf18/fbp_pharmazeutische_medizin_d.pdf.
[15] Schnetzler G, Bremgartner M F, Straessle R G, et al. Evolution to a competency-based training curriculum for pharmaceutical medicine physicians in Switzerland[J]. Front Pharmacol, 2019, 10: 164.
[16] IMI. Innovative Health Initiative[EB/OL]. (2021-12-15)[2022-10-09]. https://www.imi.europa.eu/about-imi/innovative-health-initiative.
[17] IMI. Pharmatrain: pharmaceutical medicine training programme[EB/OL]. (2015-01-31)[2022-10-09]. https://www.imi.europa.eu/projects-results/project-factsheets/pharmatrain.
[18] Anon. The PharmaTrain Specialist in Medicines Development (SMD)[EB/OL]. (2016-10-01)[2022-10-09]. https://www.pharmatrain.eu/smd-programme-concept.
[19] Allen G M, Chisholm O. Postgraduate education in pharmaceutical medicine in Australia: evaluation and evolution to a global program over 20 years[J]. Ther Innov Regul Sci, 2019, 53(5): 654-660.
[20] MTPConnect. Overview[EB/OL]. (2022-10-07)[2022-10-09]. https://www.mtpconnect.org.au.
[21] MTPConnect. MTPConnect team[EB/OL]. (2022-10-07)[2022-10-09]. https://www.mtpconnect.org.au/Team.

制药医学发展概况及学科建设展望

The development of pharmaceutical medicine and the prospect of its discipline construction

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	陈瑞芳, 张俊敏, 张铁明. 新时代背景下高校自然科学学报的功能定位探讨——以《首都医科大学学报》为例[J]. 首都医科大学学报, 2021, 42(6): 1086-1091.
[2]	孙正. 首都医科大学口腔医学院学科建设概况[J]. 首都医科大学学报, 2010, 31(4): 523-527.
[3]	王玉记;徐艳霞;吴建辉;赵明;彭师奇. 多肽及小分子药物北京市重点实验室的五年——革新意识、钻研学问、训练人才状况分析[J]. 首都医科大学学报, 2010, 31(4): 509-513.
[4]	尤红;丛瑞;朱圣韬;张澍田. 传承与创新：首都医科大学消化病学系的发展[J]. 首都医科大学学报, 2010, 31(4): 487-491.
[5]	李坤成;戴建平;. 整合优势资源，建设国内一流的影像学科——影像医学与核医学国家重点培育学科简介[J]. 首都医科大学学报, 2010, 31(4): 492-496.
[6]	张亚卓;程小燕;桂松柏. 北京市神经外科研究所——半个世纪的发展历程[J]. 首都医科大学学报, 2010, 31(4): 469-475.
[7]	潘岳松;杜忠东;张建;李仲智. 依托重点学科重点实验室建设学院型医院[J]. 首都医科大学学报, 2010, 31(4): 451-453.
[8]	吕树铮. 庆祝首都医科大学建校50周年——心血管病专业学科建设进展[J]. 首都医科大学学报, 2010, 31(4): 446-450.